Vulvar Disease in Nigeria Observational Study
Launched by KDRS LTD · May 25, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
**Summary of the Vulvar Disease in Nigeria Observational Study**
This clinical trial is looking into vulvar diseases, which are conditions that affect the external female genital area. The study aims to understand how aware patients and healthcare providers are about these conditions, as well as how common they really are in different communities across Nigeria. By gathering this information, researchers hope to improve awareness and treatment options for women experiencing these health issues.
The study is currently recruiting participants who are biological females aged between 3652 to 32871 days (approximately 10 to 90 years old). If you are a woman and interested in participating, you can share your experiences and insights about vulvar diseases. There are no specific exclusions for potential participants, meaning if you identify as female, you may be eligible. Participants can expect to share their experiences in a supportive environment, contributing to important research that could help other women in Nigeria. Your participation could make a real difference in understanding and addressing vulvar diseases.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • biological females - afab
- Exclusion Criteria:
- • none-afab
About Kdrs Ltd
KDRS Ltd. is a leading clinical trial sponsor dedicated to advancing innovative healthcare solutions through rigorous research and development. With a focus on enhancing patient outcomes, KDRS Ltd. specializes in designing and managing clinical trials across various therapeutic areas, leveraging cutting-edge methodologies and technologies. Committed to upholding the highest ethical standards, the company collaborates with healthcare professionals, regulatory bodies, and industry stakeholders to ensure the safety and efficacy of new treatments. KDRS Ltd. is positioned at the forefront of clinical research, striving to bring groundbreaking therapies to market that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported